Karin Jandeleit-Dahm

Prof. Karin Jandeleit-Dahm


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Biology
Verified
Journal Article
Open access
PDF file
ACAmelia Charlton
Amelia Charlton
JGJessica Garzarella
Jessica Garzarella
Karin Jandeleit-DahmKarin Jandeleit-Dahm
Karin Jandeleit-Dahm
Jay C. JhaJay C. Jha
Jay C. Jha
Oxidative stress and inflammation are considered major drivers in the pathogenesis of diabetic complications, including renal and cardiovascular disease. A symbiotic relationship also appears to exist between oxidative stress and inflammation. Several emerging therapies target these crucial pathways, to alleviate the burden of the aforementioned diseases. Oxidative stress refers to an imbalance between reactive oxygen species (ROS) and antioxidant defenses, a pathological state which not only leads to direct cellular damage but also an inflammatory cascade that further perpetuates tissue injury. Emerging therapeutic strategies tackle these pathways in a variety of ways, from increasing antioxidant defenses (antioxidants and Nrf2 activators) to reducing ROS production (NADPH oxidase inhibitors and XO inhibitors) or inhibiting the associated inflammatory pathways (NLRP3 inflammasome inhibitors, lipoxins, GLP-1 receptor agonists, and AT-1 receptor antagonists). This review summarizes the mechanisms by which oxidative stress and inflammation contribute to and perpetuate diabetes associated renal and cardiovascular disease along with the therapeutic strategies which target these pathways to provide reno and cardiovascular protection in the setting of diabetes.

30 August 2018 in Clinical Science
Verified
Journal Article
Closed access
PDF file
JJJay C. Jha
Jay C. Jha
FHFlorence Ho
Florence Ho
CDChristopher Dan
Christopher Dan
Karin Jandeleit-DahmKarin Jandeleit-Dahm
Karin Jandeleit-Dahm
Chronic renal and vascular oxidative stress in association with an enhanced inflammatory burden are determinant processes in the development and progression of diabetic complications including cardiovascular disease (CVD), atherosclerosis and diabetic kidney disease (DKD). Persistent hyperglycaemia in diabetes mellitus increases the production of reactive oxygen species (ROS) and activates mediators of inflammation as well as suppresses antioxidant defence mechanisms ultimately contributing to oxidative stress which leads to vascular and renal injury in diabetes. Furthermore, there is increasing evidence that ROS, inflammation and fibrosis promote each other and are part of a vicious connection leading to development and progression of CVD and kidney disease in diabetes.

26 July 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
JJJay C. Jha
Jay C. Jha
CBClaudine Banal
Claudine Banal
JOJun Okabe
Jun Okabe
SGStephen P. Gray
Stephen P. Gray
THThushan Hettige
Thushan Hettige
Karin Jandeleit-DahmKarin Jandeleit-Dahm
Karin Jandeleit-Dahm
NADPH oxidase–derived excessive production of reactive oxygen species (ROS) in the kidney plays a key role in mediating renal injury in diabetes. Pathological changes in diabetes include mesangial expansion and accumulation of extracellular matrix (ECM) leading to glomerulosclerosis. There is a paucity of data about the role of the Nox5 isoform of NADPH oxidase in animal models of diabetic nephropathy since Nox5 is absent in the mouse genome. Thus, we examined the role of Nox5 in human diabetic nephropathy in human mesangial cells and in an inducible human Nox5 transgenic mouse exposed to streptozotocin-induced diabetes. In human kidney biopsies, Nox5 was identified to be expressed in glomeruli, which appeared to be increased in diabetes. Colocalization demonstrated Nox5 expression in mesangial cells. In vitro, silencing of Nox5 in human mesangial cells was associated with attenuation of the hyperglycemia and TGF-β1–induced enhanced ROS production, increased expression of profibrotic and proinflammatory mediators, and increased TRPC6, PKC-α, and PKC-β expression. In vivo, vascular smooth muscle cell/mesangial cell–specific overexpression of Nox5 in a mouse model of diabetic nephropathy showed enhanced glomerular ROS production, accelerated glomerulosclerosis, mesangial expansion, and ECM protein (collagen IV and fibronectin) accumulation as well as increased macrophage infiltration and expression of the proinflammatory chemokine MCP-1. Collectively, this study provides evidence of a role for Nox5 and its derived ROS in promoting progression of diabetic nephropathy.

15 December 2020 in Diabetes
Verified
Journal Article
Closed access
PDF file
ASArpeeta Sharma
Arpeeta Sharma
JCJudy S.Y. Choi
Judy S.Y. Choi
NSNada Stefanovic
Nada Stefanovic
AAAnnas Al-Sharea
Annas Al-Sharea
DSDaniel S. Simpson
Daniel S. Simpson
JHJudy B. de Haan
Judy B. de Haan
Low-grade persistent inflammation is a feature of diabetes-driven vascular complications, in particular activation of the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome to trigger the maturation and release of the inflammatory cytokine interleukin-1β (IL-1β). We investigated whether inhibiting the NLRP3 inflammasome, through the use of the specific small-molecule NLRP3 inhibitor MCC950, could reduce inflammation, improve vascular function, and protect against diabetes-associated atherosclerosis in the streptozotocin-induced diabetic apolipoprotein E-knockout mouse. Diabetes led to an approximately fourfold increase in atherosclerotic lesions throughout the aorta, which were significantly attenuated with MCC950 (P < 0.001). This reduction in lesions was associated with decreased monocyte–macrophage content, reduced necrotic core, attenuated inflammatory gene expression (IL-1β, tumor necrosis factor-α, intracellular adhesion molecule 1, and MCP-1; P < 0.05), and reduced oxidative stress, while maintaining fibrous cap thickness. Additionally, vascular function was improved in diabetic vessels of mice treated with MCC950 (P < 0.05). In a range of cell lines (murine bone marrow–derived macrophages, human monocytic THP-1 cells, phorbol 12-myristate 13-acetate–differentiated human macrophages, and aortic smooth muscle cells from humans with diabetes), MCC950 significantly reduced IL-1β and/or caspase-1 secretion and attenuated leukocyte–smooth muscle cell interactions under high glucose or lipopolysaccharide conditions. In summary, MCC950 reduces plaque development, promotes plaque stability, and improves vascular function, suggesting that targeting NLRP3-mediated inflammation is a novel therapeutic strategy to improve diabetes-associated vascular disease.

13 January 2025 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
AKAbdul Waheed Khan
Abdul Waheed Khan
Karin Jandeleit-DahmKarin Jandeleit-Dahm
Karin Jandeleit-Dahm

13 September 2018 in Diabetes
Verified
Journal Article
Closed access
PDF file
EBEoin Brennan
Eoin Brennan
MMMuthukumar Mohan
Muthukumar Mohan
AMAaron McClelland
Aaron McClelland
MGMonica de Gaetano
Monica de Gaetano
CTChristos Tikellis
Christos Tikellis
PKPhillip Kantharidis
Phillip Kantharidis
Increasing evidence points to the fact that defects in the resolution of inflammatory pathways predisposes individuals to the development of chronic inflammatory diseases, including diabetic complications such as accelerated atherosclerosis. Resolution of inflammation is dynamically regulated by the production of endogenous modulators of inflammation, including lipoxin A4 (LXA4). Here, we explored the therapeutic potential of LXA4 and a synthetic LX analogue [Benzo-LXA4] to modulate diabetic complications in the streptozotocin-induced diabetic ApoE-/- mice and in human carotid plaque tissue ex vivo. The development of diabetes-induced aortic plaques and inflammatory responses of aortic tissue including expression of vcam1, mcp-1, il-6 and il-1β was significantly attenuated by both LXA4 and Benzo-LXA4 in diabetic ApoE-/- mice. Importantly, in mice with established atherosclerosis, treatment with LXs for a 6 week period, initiated 10 weeks after diabetes onset, led to a significant reduction in aortic arch plaque development [19.22±2.01% (diabetic); 12.67±1.68% (diabetic+LXA4); 13.19±1.97% (diabetic+Benzo-LXA4)]. Secretome profiling of human carotid plaque explants treated with LXs indicated changes to proinflammatory cytokine release, including TNF-α and IL-1β. LXs also inhibited PDGF-stimulated vascular smooth muscle cells proliferation and transmigration and endothelial cell inflammation. These data suggest that LXs may have therapeutic potential in the context of diabetes associated vascular complications.